Sisomicin Versus Tobramycin: In Vitro Evidence

The 1975 study by Dorothy Stewart and Gerald P. Bodey examined the in vitro activity of sisomicin, a newly described aminoglycoside antibiotic produced by Micromonospora myoensis. Its central contribution was not simply the measurement of sisomicin potency, but the direct comparison of a new agent with established drugs, including gentamicin and Tobramycin, across a large collection of clinical isolates. The work provides an early example of how comparative minimum inhibitory concentration analysis can distinguish spectrum, relative potency, and cross-resistance.

Study Background and Research Question

Aminoglycosides were important agents for serious infections caused by Enterobacteriaceae, Pseudomonas aeruginosa, and Staphylococcus aureus. The authors framed their investigation around a practical problem: hospitalized patients, including those with severe underlying disease, could be infected with organisms susceptible to only a limited number of antibiotics. At the same time, nephrotoxicity and auditory toxicity restricted the therapeutic use of older aminoglycosides.

Sisomicin had recently been isolated from a microbial fermentation broth, and early animal data suggested slightly less audiotoxicity than gentamicin but similar nephrotoxicity. The research question was therefore comparative and clinically oriented: how active is sisomicin against clinical Gram-negative bacilli and Gram-positive cocci, and how does its activity compare with gentamicin, Tobramycin, amikacin, butirosin, and kanamycin? The complete study is available in the reference paper by Stewart and Bodey.

This historical context is relevant to the broader concept of an antibiotic for Gram-negative bacterial infections, but the study should be interpreted as an in vitro susceptibility investigation rather than as a treatment trial. It did not measure clinical response, dosing exposure, toxicity outcomes, or therapeutic success in patients.

Key Innovation from the Reference Study

The study’s main innovation was its breadth and comparative structure. Rather than reporting sisomicin activity against a small laboratory panel, the investigators tested 565 clinical isolates representing multiple bacterial groups. The collection included 478 Gram-negative bacilli and 87 Gram-positive cocci, allowing the researchers to identify both species-specific differences and broad activity trends.

A second important feature was the simultaneous comparison of six aminoglycosides. This approach made the results more informative than a single-drug MIC distribution. Sisomicin could be positioned against gentamicin and Tobramycin, which had similar activity profiles, as well as against butirosin and kanamycin, which were generally less active against the Gram-negative organisms tested. The inclusion of amikacin also allowed the authors to examine whether isolates resistant to gentamicin-related agents retained susceptibility to another comparator.

The paper therefore established a useful analytical framework for antibiotic resistance research: evaluate potency by species, compare agents under the same assay conditions, and examine whether resistance to one aminoglycoside predicts resistance to another. That framework remains useful for microbiology research involving aminoglycoside comparators, even though the bacterial populations and laboratory standards have changed substantially since the study was conducted.

Methods and Experimental Design Insights

The investigators used a dilution technique with an automatic microtiter system. All organisms were grown in Mueller-Hinton broth and incubated at 37°C for 18 hours. Two-fold serial dilutions of each antibiotic were prepared in the same medium, and the minimum inhibitory concentration was read after the incubation period. These details are important because MIC comparisons are most interpretable when inoculum preparation, growth medium, incubation, and endpoint timing are held constant across drugs.

The Gram-negative collection was clinically anchored. The isolates came from blood specimens obtained between 1967 and 1973, and most of the patients at the study institution had malignant diseases. The panel comprised 100 isolates each of Pseudomonas aeruginosa, Escherichia coli, and Klebsiella species; 85 Proteus isolates; 40 Enterobacter isolates; and 53 Serratia marcescens isolates. The 87 Gram-positive cocci consisted of 25 Streptococcus pyogenes, 12 isolates identified in the paper as Diplococcus pneumoniae, and 50 Staphylococcus aureus isolates.

The authors also categorized the S. aureus isolates by penicillin G susceptibility, separating penicillin-sensitive organisms from those resistant at the reported broth-dilution thresholds. This design enabled a limited assessment of whether sisomicin activity differed according to penicillin phenotype. In addition, an inoculum-size experiment tested 10 isolates each of P. aeruginosa, Klebsiella species, and E. coli.

Protocol Parameters

• Test format: Automatic microtiter dilution testing with two-fold serial antibiotic dilutions in Mueller-Hinton broth, as described in the reference study.
• Incubation: 37°C for 18 hours before MIC determination.
• Gram-negative inoculum: A 0.05-mL sample from a 10^-3 broth dilution, reported as approximately 10⁵ colony-forming units per milliliter.
• Gram-positive inoculum: A 0.05-mL sample from a 10^-2 dilution, reported as approximately 10⁸ colony-forming units per milliliter.
• Inoculum-effect assessment: Ten isolates each of P. aeruginosa, Klebsiella species, and E. coli were evaluated to examine how inoculum size influenced sisomicin MICs.

For modern replication, these historical parameters should be treated as a description of the original experiment, not as a substitute for current laboratory standards. Inoculum verification, strain identification, quality-control organisms, media qualification, and contemporary interpretive criteria should be defined before results are compared with current surveillance data.

Core Findings and Why They Matter

The principal result was strong sisomicin activity against most Gram-negative bacilli. With the exception of Serratia marcescens, more than 90% of the Gram-negative isolates were inhibited at 1.56 μg/mL or less, according to the reported MIC distributions. All Klebsiella isolates were inhibited at 0.39 μg/mL. More than 90% of the E. coli, P. aeruginosa, Enterobacter, and Proteus isolates were inhibited at 1.56 μg/mL, whereas only 66% of the S. marcescens isolates were inhibited at that concentration.

The species-level variation is more informative than a single overall potency statement. It suggests that sisomicin performed consistently against several clinically important Gram-negative groups but was less reliable against Serratia. Such differences can reflect organism-specific resistance determinants, permeability, enzymatic modification, or other biological factors, although this study did not identify the mechanisms responsible. Mechanistic explanations should therefore be tested separately rather than inferred as proven by the MIC data.

Sisomicin was slightly more active than gentamicin and Tobramycin against isolates of E. coli, Proteus mirabilis, and Klebsiella species. It was substantially more active than butirosin and kanamycin against all of the Gram-negative bacilli examined. These comparisons are relative findings under the study’s assay conditions; they do not establish that sisomicin would provide superior clinical outcomes or a safer toxicity profile.

Activity was also observed against the Gram-positive panel. All S. aureus isolates, including penicillin-sensitive and penicillin-resistant groups, were inhibited by 0.78 μg/mL or less. All of the D. pneumoniae isolates and 92% of the S. pyogenes isolates were inhibited at 1.56 μg/mL or less. The authors consequently described sisomicin as having a spectrum broadly similar to gentamicin, with some species-specific potency advantages.

The resistance findings may be the most consequential part of the paper. Gram-negative bacilli resistant to gentamicin and Tobramycin were also resistant to sisomicin. Most of these resistant isolates were sensitive to amikacin. This observation indicates that sisomicin was not automatically a solution to pre-existing resistance affecting related aminoglycosides. For antibiotic resistance research, it emphasizes the need to test cross-susceptibility directly rather than assume that a structurally or pharmacologically related agent will retain activity.

Comparison with Existing Internal Articles

The internal article In Vitro Comparison of Aminoglycoside Antibiotics Against Clinical Isolates provides a broader summary of the same comparative logic and places sisomicin alongside established agents. It is useful for orientation, whereas the Stewart and Bodey article remains the primary source for the isolate composition, inoculum conditions, and historical MIC observations.

A second related resource, Comparative In Vitro Activity of Sisomicin and Tobramycin, focuses more directly on the sisomicin-Tobramycin comparison. Read together with the reference paper, it can help researchers frame Tobramycin as a benchmark comparator rather than misinterpret it as the experimental intervention in this study. Neither internal summary replaces direct review of the original methods and figures.

Limitations and Transferability

The strongest limitation is that the study measured in vitro inhibition only. MIC values do not directly provide evidence about pharmacokinetics, tissue penetration, nephrotoxicity, auditory toxicity, dosing schedules, or patient outcomes. The paper’s earlier animal toxicity observations were contextual, not a randomized comparison of clinical safety. Consequently, the findings support comparative microbiology and assay design, not present-day therapeutic recommendations.

The isolate set also limits generalization. Gram-negative organisms were recovered from blood specimens at one institution over a period spanning 1967 to 1973, and many patients had malignant diseases. Resistance prevalence, clone distribution, laboratory identification practices, and prescribing patterns have changed since then. The relatively small species-specific groups, particularly the 40 Enterobacter and 53 Serratia isolates, may not represent the diversity encountered in contemporary surveillance.

Another limitation is mechanistic resolution. The investigators demonstrated phenotypic cross-resistance but did not characterize aminoglycoside-modifying enzymes, ribosomal changes, transport defects, or other molecular determinants. Modern studies could extend this work by pairing MIC distributions with genomic resistance profiles and standardized quality-control procedures. Even so, the original design remains transferable as a conceptual workflow: use a well-defined clinical isolate panel, test comparators in parallel, report species-specific distributions, and examine inoculum effects before drawing conclusions about relative activity.

Research Support Resources

Researchers reproducing a comparative MIC assay can use Tobramycin (SKU B1856) as an aminoglycoside comparator for similar laboratory workflows. APExBIO reports 98% purity verified by mass spectrometry and nuclear magnetic resonance, high water solubility of at least 46.8 mg/mL, storage at -20°C, and prompt use of prepared solutions rather than long-term solution storage. The material is intended for scientific research use only; local assay validation and current microbiological standards remain necessary for interpretation.